Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.44 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2197298 | 0.87 | HPGD (0.33) | CYP19A1CYP17A1GABBR2GABRB1GABRB2 | |
| SCHEMBL7705806 | 0.81 | PAM (0.49) | CYP19A1CYP17A1GABBR2GABRB1GABRB2 | |
| SCHEMBL2194804 | 0.80 | GABBR2 (0.42) | CYP19A1CYP17A1GABBR2GABRB1GABRB2 | |
| SCHEMBL28018052 | 0.76 | CYP19A1 (0.50) | CYP19A1CYP17A1KMT2AMEN1ALDH1A1 | |
| SCHEMBL1397068 | 0.76 | KMT2A (0.48) | CYP19A1GABBR2GABRB1GABRB2GABBR1 | |
| SCHEMBL6066461 | 0.76 | KMT2A (0.48) | CYP19A1GABBR2GABRB1GABRB2GABBR1 | |
| SCHEMBL1397163 | 0.75 | CHRNA7 (0.42) | GABBR2GABRB1GABRB2GABBR1CHRNA7 | |
| SCHEMBL11908382 | 0.74 | CYP19A1 (0.45) | CYP19A1CYP17A1KMT2AMEN1ALDH1A1 | |
| SCHEMBL6305516 | 0.72 | GABBR2 (0.41) | CYP19A1CYP17A1GABBR2GABRB1GABRB2 | |
| SCHEMBL6687185 | 0.71 | PAM (0.52) | CYP19A1KMT2AMEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3253735-B1 | LATENT ACIDS AND THEIR USE | BASF SE (DE) | 2021-03-31 | — | — | EP | disclosed |
| US-20180009775-A1 | LATENT ACIDS AND THEIR USE | BASF SE (DE) | 2018-01-11 | — | — | US | disclosed |
| WO-2016124493-A1 | LATENT ACIDS AND THEIR USE | BASF SE (DE) | 2016-08-11 | — | — | WO | disclosed |
| EP-2197840-B1 | SULPHONIUM SALT INITIATORS | BASF SE (DE) | 2013-11-06 | — | — | EP | disclosed |
| EP-2197869-B1 | SULPHONIUM SALT INITIATORS | BASF SE (DE) | 2013-04-24 | — | — | EP | disclosed |
| EP-1472576-B1 | SULFONATE DERIVATIVES AND THE USE THEROF AS LATENT ACIDS | BASF SE (DE) | 2013-04-24 | — | — | EP | disclosed |
| EP-2197839-B1 | SULPHONIUM SALT INITIATORS | BASF SE (DE) | 2013-01-02 | — | — | EP | disclosed |
| EP-2349993-B1 | SULFONIUM DERIVATIVES AND THE USE THEROF AS LATENT ACIDS | BASF SE (DE) | 2012-12-12 | — | — | EP | disclosed |
| EP-2349993-A1 | SULFONIUM DERIVATIVES AND THE USE THEROF AS LATENT ACIDS | BASF SE (DE) | 2011-08-03 | — | — | EP | disclosed |
| US-20110171569-A1 | SULFONIUM DERIVATIVES AND THE USE THEROF AS LATENT ACIDS | BASF SE (DE) | 2011-07-14 | — | — | US | disclosed |
| EP-1392675-B1 | SUBSTITUTED OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS | CIBA SC HOLDING AG (CH) | 2005-02-09 | — | — | EP | disclosed |
| EP-1472576-A2 | SULFONATE DERIVATIVES AND THE USE THEROF AS LATENT ACIDS | Ciba SC Holding AG (CH) | 2004-11-03 | — | — | EP | disclosed |
| EP-1392675-A1 | SUBSTITUTED OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS | Ciba SC Holding AG (CH) | 2004-03-03 | — | — | EP | disclosed |
| EP-1344109-A2 | ONIUM SALTS AND THE USE THEROF AS LATENT ACIDS | Ciba SC Holding AG (CH) | 2003-09-17 | — | — | EP | disclosed |
| WO-2003067332-A2 | SULFONATE DERIVATIVES AND THE USE THEROF AS LATENT ACIDS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2003-08-14 | — | — | WO | disclosed |
| EP-1320785-A2 | OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS | Ciba SC Holding AG (CH) | 2003-06-25 | — | — | EP | disclosed |
| WO-2002098870-A1 | SUBSTITUTED OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2002-12-12 | — | — | WO | disclosed |
| WO-2002046507-A2 | ONIUM SALTS AND THE USE THEROF AS LATENT ACIDS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2002-06-13 | — | — | WO | disclosed |
| WO-2002025376-A2 | OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2002-03-28 | — | — | WO | disclosed |
| US-6261738-B1 | LATENT CURING CATALYSTS FOR PHOTORESISTS SUCH AS 2,2,2-TRIFLUORO-1-PHENYL-ETHANONE OXIME-O-METHYL SULFONATE | CIBA SPECIALTY CHEMICALS CORPORATION | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009775-A1 | LATENT ACIDS AND THEIR USE | LTA, C1S, C9 | CYP19A1 355/4885CYP17A1 1244/4885GABBR2 985/4885 |
| US-20110171569-A1 | SULFONIUM DERIVATIVES AND THE USE THEROF AS LATENT ACIDS | NR2E3, HCAR3, HRH4 | CYP19A1 1750/4885CYP17A1 1769/4885GABBR2 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.